SapVax, a BioMotiv portfolio company developing a suite of cancer vaccines based on novel self-adjuvanting peptide technology, has achieved a significant proof-of-principle milestone, expanded its Scientific Advisory Board, and closed a new round of equity financing to continue to advance its unique platform towards the clinic.

The company recently demonstrated that its vaccines can activate human T cells in a key experiment. In addition, SapVax expanded its Scientific Advisory Board (SAB) which is chaired by Howard Kaufman, MD, the Chief Medical Officer at Replimune Group and Immediate Past President of the Society for Immunotherapy of Cancer.

Read full press release here.